SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD

Review checklist: Rachel Carson (HR-ML041)
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
- 16judgment calls in the dossier
- 1protocol deviations
- 3orders and referrals without results in the record
- 0evidence items to check (retrospective or sensitive claims, unconfirmed diagnoses)
Review status
| Review | Status | Reviewer | Date | Notes |
|---|
| schema validation | not_started | | | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | | | Awaiting clinician review; check omission of axillary dissection with two positive sentinel nodes, regional nodal radiation, omission of chemotherapy at recurrence score 17, the adjuvant ribociclib choice and its monitoring, and adjuvant zoledronic acid. |
| provenance review | not_started | | | Her illness is documented from the Science History Institute, the National Park Service, the Rachel Carson Council, a Gale reference biography, a journal review of the standard biography, her biographer's headnote to a letter, a news feature, and a magazine article; the 1950 operation rests on one popular biography and is graded probable. The surgeon is not named; no relative or friend is quoted. |
| safe messaging review | not_started | | | No behavioral-health diagnosis; mild distress at diagnosis is screened and supported; her documented wish for privacy is respected; death recorded without detail. |
Judgment calls (dossier editorial resolutions)
- Teaching contrast: the 1960 nondisclosure. The documented history is that her surgeon told her the tumor was not cancer, or "a condition bordering on malignancy," even after a radical mastectomy, and that she had to fight the medical profession for the truth (sources 5, 6, 7). This was the usual practice of the time: in a 1961 survey 90 percent of physicians preferred not to tell (sources 12 and 13). The synthetic episode is built as the opposite. At every result she is first asked what she wants to know, then told in person and in plain words, with a written copy and teach-back, and each treatment decision is hers, as AMA Opinion 2.1.3 and the ASCO communication guideline require. The surgeon of 1960 is not named in the record, and his words appear only as reported in the cited sources.
- How she learned the truth. The sources say that she learned later in 1960 that the cancer had spread, and that she sought the truth from another physician, George Crile Jr., whom her biographer calls her cancer surgeon and friend. No fetched source says who first told her, or exactly when, so the record does not say. A Wikipedia account citing the Lear biography says she learned in December 1960; it was not used as a source, and the timeline event is dated "Late 1960" (approximate).
- The 1950 operation. Only one popular biography (source 11) gives the 1950 removal of a benign left breast tumor, and the same source dates the second operation to 1959 rather than 1960. The claim is graded D with certainty probable. Another account found in search dated a first breast operation to 1946; it was not fetched and is not used. The synthetic history refers to a benign tumor removed "about ten years ago."
- Arthritis and the other illnesses. A reference biography lists flu, a sinus infection, heart trouble, arthritis, and an ulcer among the illnesses of the Silent Spring years, without dates, and a review of the standard biography says she called her disability "arthritis" to hide the cancer. So the modern knee osteoarthritis is synthetic and is not linked to that claim. The modern duodenal ulcer with Helicobacter pylori (resolved by the test of cure) and the sinus illness at the sick visit echo the documented ulcer and sinus infection, but are not linked to the claim, because the sources do not date them. Her documented angina and the later spread to nodes, bones, and liver are not used in the episode.
- Privacy. Her documented choice to hide her cancer from all but a few friends (source 7) is echoed as her own modern request that her diagnosis be shared only with the people she names. The intake documents show this as her present wish, not as the later historical fact.
- Index age and dates. She found lumps in her left breast in early 1960 and had a radical mastectomy in April 1960, at 52. The index visit on March 9, 2026 maps to March 9, 1960, before the operation, when she was 52, so the synthetic date of birth is May 27, 1973 (shift 66 years). The other visits (March 18, April 20, June 15, July 20, September 8, and October 13, 2026) map to the same days of 1960; the synthetic lumpectomy on April 6, 2026 maps to April 6, 1960, in the documented month of her operation, but no exact date of the 1960 operation is asserted. All visits fall within her lifetime and contradict no documented event.
- Postmenopausal status. Her menopausal status in 1960 is not given in any fetched source. A search summary of a 2014 ASCO article described her as premenopausal in April 1960; the full article could not be read. The synthetic episode makes her postmenopausal (menopause at 51), which decides the choice of letrozole without ovarian suppression. This is a synthetic choice for the teaching episode, not a historical assertion.
- Stage and treatment. Decided: early, curable disease in the modern episode, a deliberate counterfactual to her documented course. Clinical stage cT2 cN0, then pT2 pN1a(sn) with two of three sentinel nodes involved (anatomic stage IIB), grade 2, ER and PR positive, HER2 negative, Ki-67 22 percent, recurrence score 17. This was chosen to differ from the earlier breast cancer records (stage I to IIA node-negative disease, mastectomy, and survivorship care) and to teach the management of one or two positive sentinel nodes without axillary dissection, the omission of chemotherapy in a postmenopausal woman with one to three nodes and a recurrence score of 25 or less, and adjuvant ribociclib, for which stage II node-positive disease qualifies. She chose breast-conserving surgery over mastectomy; radiation to the whole breast and regional nodes; letrozole with ribociclib for three years; and adjuvant zoledronic acid. The 3-percentage-point benefit quoted for ribociclib comes from the NATALEE trial (three-year invasive disease-free survival about 90 versus 87 percent) and is a teaching approximation.
- Sick visit. An unscheduled sick visit on July 20, 2026 (true frame July 20, 1960) for acute viral rhinosinusitis on day 8 of the second ribociclib cycle, with expected grade 2 neutropenia and no fever. It teaches the distinction between viral and bacterial sinusitis, the febrile neutropenia warning, continuing ribociclib for grade 2 neutropenia, and avoiding QT-prolonging antibiotics. It does not insinuate an undocumented real diagnosis.
- Preventive visit. An adult preventive visit (age 53, so `preventive_adult`) on October 13, 2026 (true frame October 13, 1960). Synthetic judgment calls: the colonoscopy three years earlier and the cervical co-test two years earlier are recorded as normal history; hepatitis B, hepatitis C, and HIV screening are ordered with no results; the advance care planning names no real person as her health care agent, and its first instruction is that she always be told the truth.
- Focused visits. The four chronic-care follow-ups (diagnosis, two weeks after surgery, the start of adjuvant therapy, and the start of the fourth ribociclib cycle) are documented as focused visits on the NCCN breast cancer workup, the ribociclib prescribing information, the ASCO bone-modifying agent guideline, and the CMID breast cancer monograph. Each lists every item the protocol calls for at that point, including the items not indicated (breast MRI, staging scans, tumor markers). One protocol deviation is recorded: the ECG due at about day 14 of the first ribociclib cycle was missed while she was away for field work; it was done at the start of the second cycle (QTcF 426 ms), so no harm resulted, and the corrective action is recorded. The ribociclib blood tests between visits, done by the oncology team, are reported in prose (neutrophils 1.3 to 1.7, normal liver tests and electrolytes) and are not observations; the germline result, the recurrence score, and the urea breath test are also reported in prose or as procedures.
- Consultation. The breast surgical oncology referral and the consultation by Henrietta Solís-Abernathy, MD (a fictional consultant), on the day of the second visit, are S. The consultant answers the five referral questions with what the record shows happened afterwards: breast-conserving surgery, her choice after mastectomy was explained; no MRI or staging scans; sentinel node biopsy, with no axillary dissection for one or two positive nodes; germline testing before surgery (negative); and a recurrence score and multidisciplinary review, which led to radiation, letrozole, ribociclib, and zoledronic acid without chemotherapy. Medical and radiation oncology are unnamed teams.
- Other clinicians and people. No real relative, friend, editor, or physician is the source of any modern statement or decision. Crile is named only in a documented claim, as her biographer describes him. The physicians named in her 1963 letter are not named in the record. Her later public life and death are recorded only as claims.
- Family history. No family medical history is recorded; none was found in the fetched sources, and none is synthesized.
- Presenting concern. The intake documents list the presenting concern (PRB-003, a new left breast lump) rather than the breast cancer, which is recorded from the biopsy-results visit; the presenting concern is resolved, superseded by the diagnosis, from that visit on. The axillary nodal disease (PRB-006) is recorded from the post-operative visit.
- Carson died in 1964, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.
Protocol deviations
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|
2026-09-08 Progress note 06 (C-CDA) | ECG at about day 14 of the first cycle | Day 14 of cycle 1 | Missed, a deviation from the protocol: she was away for field work and the ECG was not booked with her blood test. It was done at the start of cycle 2 instead, QTcF 426 ms, normal, so no harm resulted. Corrective action: the oncology scheduler now books ECGs with the blood tests and confirms by telephone; any dose change or new QT-prolonging drug will prompt a repeat ECG |
Orders and referrals without results in the record
| Visit | Type | Item | Status | Detail |
|---|
2026-04-20 Progress note 03 (C-CDA) | Imaging | Bone density (DXA) | Ordered | Booked for the day letrozole starts |
2026-04-20 Progress note 03 (C-CDA) | Medication safety | Dental assessment before zoledronic acid | Ordered | Dental check booked before the first infusion |
2026-10-13 Progress note 07 (C-CDA) | Prevention | Hepatitis B, hepatitis C, and HIV screening | Ordered | One-time screening; no prior result on record; drawn today, results pending |
Evidence to check
Retrospective claims (R)
None.
Sensitive claims
None.
Diagnoses not confirmed
None.
Notes to read
Every note in the record, with its type. All clinical content is synthetic.
Abnormal results
| Date | Result | Value | Flag |
|---|
| 2026-06-15 | Total cholesterol | 208 mg/dL (high) | High |
| 2026-06-15 | LDL cholesterol | 124 mg/dL (high) | High |
| 2026-06-15 | 25-hydroxyvitamin D | 22 ng/mL (low) | Low |
| 2026-06-15 | Lumbar spine T-score (DXA) | -1.8 (low) | Low |
| 2026-06-15 | Femoral neck T-score (DXA) | -1.3 (low) | Low |
| 2026-09-08 | White cell count | 3.4 10*3/uL (low) | Low |
| 2026-09-08 | Absolute neutrophil count | 1.6 10*3/uL (low) | Low |
| 2026-07-20 | White cell count | 2.9 10*3/uL (low) | Low |
| 2026-07-20 | Absolute neutrophil count | 1.2 10*3/uL (low) | Low |